Novartis names once-yearly zoledronic acid Aclasta
Aclasta will be the trade name for Novartis' once-yearly I.V. infusion formulation of zoledronic acid for treatment of Paget's disease. The priority review date on the Aclasta NDA is in March, the company said. Novartis anticipates a 2007 filing of Aclasta in treatment of osteoporosis (1"The Pink Sheet" Nov. 24, 2003, p. 29). Novartis also markets zoledronic acid under the trade name Zometa for treatment of prostate cancer...
You may also be interested in...
Further study of jaw osteonecrosis risk may differentiate Novartis' bisphosphonates Zometa and Aredia, FDA Division of Oncology Drug Products Director Richard Pazdur suggested
Novartis' clinical R&D portfolio has grown 44% over the last four years, with new molecular entities representing about half the drugs in development, Global Pharma Development Head Joerg Reinhardt, PhD, said Nov. 19 during Novartis' R&D day in New York
BridgeBio Pharma’s affiliate QED Therapeutics granted and Helsinn Group exclusive global rights (excluding Greater China) to the FGFR1-3 inhibitor infigratinib in oncology and all other indications except skeletal dysplasias (including achondroplasia). BridgeBio could see up to $2.45bn in payments from the deal, including over $100m in up-front, regulatory, and launch payments, and the remainder in sales milestones. In the month’s top M&A, Amgen entered into an agreement to acquire fellow public biotech Five Prime Therapeutics for about $1.9bn, gaining Phase III-ready bemarituzumab for frontline advanced gastric or gastroesophageal junction cancer.